Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients

PHASE4UnknownINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

May 3, 2017

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2022

Conditions
Crohn Disease in RemissionCrohn Disease
Interventions
OTHER

Lengthening adalimumab dosing interval

Lengthening adalimumab dosing interval from 2 weeks to 3 weeks and -later- to 4 weeks.

Trial Locations (22)

6500 HB

Radboudumc University Nijmegen Medical Centre, Nijmegen

PO box 90153, 5200 ME

Jeroen Bosch Ziekenhuis, 's-Hertogenbosch

PO box 90157, 4800 RL

Amphia Ziekenhuis, Breda

PO box 707, 5400 AS

Bernhoven, Uden

Unknown

VU Medisch Centrum, Amsterdam

Flevoziekenhuis, Almere Stad

AmsterdamUMC - location AMC, Amsterdam

Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam

Reinier de Graaf, Delft

Maxima Medisch Centrum, Eindhoven

Medisch Spectrum Twente, Enschede

Zuyderland ziekenhuis, Geleen

Spaarne Gasthuis, Haarlem

Leids Universitair Medisch Centrum, Leiden

Maastricht UMC+, Maastricht

Canisius Wilhelmina Ziekenhuis, Nijmegen

Elisabeth-TweeSteden Ziekenhuis, Tilburg

PO box 444, 3300 AK

Albert Schweitzer Ziekenhuis, Dordrecht

PO box 10900, 3004 BA

Franciscus Gasthuis & Vlietland, Rotterdam

PO box 2040, 3000 CA

Erasmus Medical Center, Rotterdam

PO box 5009, 3008 AA

Ikazia Ziekenhuis, Rotterdam

PO box 85500, 3508 GA

UMC Utrecht, Utrecht

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Erasmus Medical Center

OTHER

lead

Radboud University Medical Center

OTHER

NCT03172377 - Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients | Biotech Hunter | Biotech Hunter